Ironwood Pharmaceuticals (IRWD) Revenue (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Revenue across 17 years of filings, most recently posting $113.0 million for Q2 2026.

• In Q2 2026, Revenue rose 32.62% year-over-year to $113.0 million; the TTM figure through Jun 2026 stood at $389.3 million (up 26.19% YoY), while the FY2025 annual figure was $296.2 million, down 15.72% from the prior year.
• Revenue came in at $113.0 million for Q2 2026 at Ironwood Pharmaceuticals, up from $106.5 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $122.1 million in Q3 2025 to a low of $41.1 million in Q1 2025.
• Average Revenue over 5 years is $95.6 million, with a median of $100.8 million recorded in 2022.
• Year-over-year, Revenue plunged 47.31% in 2025 and surged 158.87% in 2026.
• Over 5 years, Revenue stood at $107.2 million in 2022, then increased by 9.66% to $117.6 million in 2023, then decreased by 22.98% to $90.5 million in 2024, then sank by 47.31% to $47.7 million in 2025, then soared by 136.94% to $113.0 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $113.0 million in Q2 2026, $106.5 million in Q1 2026, and $47.7 million in Q4 2025.